Aesica unveils high capacity manufacturing facility at Queenborough site

Published: 19-Sep-2013

Investment of £30m in new facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults

Aesica, the global contract development and manufacturing organisation (CDMO), has officially opened a new high capacity manufacturing facility following a £30mminvestment at its Queenborough, UK site. The 10,000m2 expansion has been constructed for the production of a solid dose medication used in treating Type 2 diabetes in adults.

Commercial production at the facility will commence in November. The facility contains a large amount of highly technical and specialist equipment, including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system.

Her Majesty’s Lord Lieutenant of Kent, Viscount De L’Isle, attended the ceremony to unveil the new facility, in recognition of the contribution that Aesica is making to the regional economy, both in terms of the creation of new jobs and commercial expansion.

Aesica is already a strong, committed, local employer in the Queenborough area and with this latest investment and expansion, the facility will have a dedicated workforce of 55 technicians who will be recruited locally and trained on site. The design of the facility will allow the current capacity to be more than doubled in the future which would require the recruitment of a further 50 staff.

The company is well established as a manufacturer and a major exporter of formulated products, and this latest investment reflects the continued growth in export demand it has experienced. The specific product manufactured at the new facility has global sales and is set for worldwide export.

'The new investment and opening of the high capacity manufacturing facility marks another key milestone for our company and a further step towards achieving our vision to be the world’s number one supplier of APIs and formulated products to the pharmaceutical industry,' said Dr Robert Hardy, CEO of Aesica Pharmaceuticals.

'The formulation of the solid dose product for the treatment of Type 2 diabetes is a perfect example of the type of high quality and high healthcare demand drugs that we manufacture for supply to the international marketplace.'

You may also like